Children's Oncology Group's 2023 blueprint for research: Bone tumors.
Bone sarcoma
Ewing sarcoma
osteosarcoma
research priorities
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
07
07
2023
accepted:
08
07
2023
pmc-release:
01
09
2024
medline:
18
8
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
The Children's Oncology Group (COG) Bone Tumor Committee is responsible for clinical trials and biological research on localized, metastatic, and recurrent osteosarcoma and Ewing sarcoma (EWS). Results of clinical trials in localized disease completed and published in the past 10 years have led to international standard-of-care chemotherapy for osteosarcoma and EWS. A recent focus on identifying disease subgroups has led to the identification of biological features associated with poor outcomes including the presence of circulating tumor DNA (ctDNA) at diagnosis, and specific genomic alterations-MYC amplification for osteosarcoma and STAG2 and TP53 mutation for EWS. Studies validating these potential biomarkers are under way. Clinical trials evaluating the addition of multitargeted kinase inhibitors, which are active in relapsed bone sarcomas, to standard chemotherapy are under way in osteosarcoma and planned in EWS. In addition, the Committee has data analyses and a clinical trial under way to evaluate approaches to local management of the primary tumor and metastatic sites. Given the rarity of bone sarcomas, we have prioritized international interactions and are in the process of forming an international data-sharing consortium to facilitate refinement of risk stratification and study of rare disease subtypes.
Identifiants
pubmed: 37501549
doi: 10.1002/pbc.30583
pmc: PMC10499366
mid: NIHMS1916211
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30583Subventions
Organisme : NCI NIH HHS
ID : U24 CA196173
Pays : United States
Organisme : NIH HHS
ID : U10CA098543
Pays : United States
Organisme : NIH HHS
ID : U24CA114766
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA098543
Pays : United States
Organisme : NIH HHS
ID : U10CA180884
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA098413
Pays : United States
Organisme : NIH HHS
ID : U10CA180899
Pays : United States
Organisme : NIH HHS
ID : U10CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA114766
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180884
Pays : United States
Organisme : NIH HHS
ID : U24CA196173
Pays : United States
Organisme : NIH HHS
ID : U10CA098413
Pays : United States
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Cancer Res. 2016 Nov 15;76(22):6657-6668
pubmed: 27697767
Nat Commun. 2022 Nov 23;13(1):7207
pubmed: 36418292
J Clin Oncol. 2019 Jun 1;37(16):1424-1431
pubmed: 31013172
JCO Precis Oncol. 2023 Mar;7:e2200334
pubmed: 36996377
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5564-73
pubmed: 25512523
Tumori. 2018 Jan-Feb;104(1):30-36
pubmed: 29218692
Eur J Cancer. 2022 Sep;172:264-275
pubmed: 35809374
ESMO Open. 2021 Oct;6(5):100250
pubmed: 34562750
Cell Growth Differ. 1996 Apr;7(4):429-37
pubmed: 9052984
Oncogene. 1997 Mar 13;14(10):1159-64
pubmed: 9121764
J Clin Oncol. 2010 Apr 20;28(12):1982-8
pubmed: 20308673
Lancet. 2022 Oct 29;400(10362):1513-1521
pubmed: 36522207
Cell Rep. 2021 Nov 23;37(8):110047
pubmed: 34818552
BMC Biol. 2023 Apr 27;21(1):98
pubmed: 37106386
Nat Med. 2018 Feb;24(2):176-185
pubmed: 29334376
Cancer. 2009 Aug 1;115(15):3526-36
pubmed: 19548262
Pediatr Blood Cancer. 2019 Feb;66(2):e27524
pubmed: 30378256
J Clin Oncol. 2021 Dec 20;39(36):4029-4038
pubmed: 34652968
Lancet Oncol. 2020 Mar;21(3):446-455
pubmed: 32078813
Nat Genet. 1994 Feb;6(2):146-51
pubmed: 8162068
Oncogene. 1995 Mar 16;10(6):1229-34
pubmed: 7700648
Arch Pathol Lab Med. 2021 Dec 1;145(12):1564-1568
pubmed: 33769463
Clin Cancer Res. 2019 Jun 1;25(11):3417-3429
pubmed: 30723142
Cancer Cell. 2021 Jun 14;39(6):827-844.e10
pubmed: 34129824
J Clin Oncol. 2015 Jul 10;33(20):2279-87
pubmed: 26033801
Cell Rep. 2014 Apr 10;7(1):104-12
pubmed: 24703847
Nat Commun. 2015 Dec 03;6:8940
pubmed: 26632267
NPJ Precis Oncol. 2022 Sep 17;6(1):65
pubmed: 36115869
Pediatr Blood Cancer. 2008 Sep;51(3):334-8
pubmed: 18506764
N Engl J Med. 1994 Aug 4;331(5):294-9
pubmed: 8022439
Cell. 2017 Sep 21;171(1):163-178.e19
pubmed: 28844694
Immunotherapy. 2021 Dec;13(17):1439-1451
pubmed: 34670399
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29251406
Cancer. 2009 Nov 15;115(22):5339-48
pubmed: 19637348
Nature. 1992 Sep 10;359(6391):162-5
pubmed: 1522903
Pediatr Blood Cancer. 2021 Dec;68(12):e29333
pubmed: 34496122
Clin Cancer Res. 2022 Jul 1;28(13):2762-2770
pubmed: 35486638
Mol Cancer Ther. 2022 Jun 1;21(6):903-913
pubmed: 35312779
Br J Cancer. 2022 Dec;127(12):2220-2226
pubmed: 36221002
Br J Cancer. 2018 Aug;119(5):615-621
pubmed: 30131550
J Clin Oncol. 2023 Apr 10;41(11):2098-2107
pubmed: 36669140
Lancet Oncol. 2019 Jan;20(1):120-133
pubmed: 30477937
Cancer. 2022 Jun 1;128(11):2107-2118
pubmed: 35226758
Cytogenet Cell Genet. 1998;82(3-4):278-83
pubmed: 9858836
Ann Oncol. 2015 Feb;26(2):407-14
pubmed: 25421877
J Natl Cancer Inst. 2011 Jun 22;103(12):962-78
pubmed: 21653923
Nat Commun. 2019 May 16;10(1):2198
pubmed: 31097696
Nat Med. 2009 Jul;15(7):750-6
pubmed: 19584866
J Clin Oncol. 2016 Sep 1;34(25):3031-8
pubmed: 27400942
PLoS Med. 2007 Apr;4(4):e122
pubmed: 17425403
Cancer Res Commun. 2023 Apr 12;3(4):564-575
pubmed: 37066022
Eur J Cancer. 2019 Nov;121:177-183
pubmed: 31586757
Clin Cancer Res. 2014 Sep 1;20(17):4584-97
pubmed: 24963049
JAMA Oncol. 2020 May 1;6(5):724-734
pubmed: 32191290
BMC Cancer. 2020 Jan 2;20(1):3
pubmed: 31898537
J Clin Oncol. 2012 Nov 20;30(33):4148-54
pubmed: 23091096
PLoS Genet. 2014 Jul 10;10(7):e1004475
pubmed: 25010205
Neoplasia. 2011 Feb;13(2):145-53
pubmed: 21403840
Eur J Cancer. 2019 Mar;109:36-50
pubmed: 30685685
Sarcoma. 2020 Dec 5;2020:3498549
pubmed: 33488267
J Clin Oncol. 2010 Apr 20;28(12):1989-94
pubmed: 20308669
Adv Exp Med Biol. 2020;1258:21-36
pubmed: 32767232
Ann Oncol. 2012 Feb;23(2):508-16
pubmed: 21527590
Cancer Discov. 2019 Jan;9(1):46-63
pubmed: 30266815
J Pathol Clin Res. 2021 Sep;7(5):425-431
pubmed: 33969640
Lancet Oncol. 2016 Oct;17(10):1396-1408
pubmed: 27569442
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Clin Cancer Res. 2016 Aug 15;22(16):4105-18
pubmed: 26979396
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734